Capital World Investors Novo Cure LTD Transaction History

Capital World Investors

$592 Billion
Q1 2025

A detailed history of Capital World Investors transactions in Novo Cure LTD stock. As of the latest transaction made, Capital World Investors holds 5,215,529 shares of NVCR stock, worth $93.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,215,529

Previous 4,815,529 8.31%

Holding current value

$93.7 Million

Previous $144 Million 35.23%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$17.82 - $30.19 $7.13 Million - $12.1 Million	400,000 Added 8.31%	5,215,529 $92.9 Million
Q4 2024 Feb 13, 2025	BUY	$14.54 - $33.41 $7.38 Million - $16.9 Million	507,311 Added 11.78%	4,815,529 $144 Million
Q3 2024 Nov 13, 2024	BUY	$15.61 - $23.34 $31.2 Million - $46.7 Million	2,000,003 Added 86.65%	4,308,218 $67.3 Million
Q1 2024 May 14, 2024	SELL	$12.42 - $17.29 $12 Million - $16.8 Million	-968,781 Reduced 29.56%	2,308,215 $36.1 Million
Q4 2023 Feb 13, 2024	SELL	$11.13 - $15.78 $62.3 Million - $88.4 Million	-5,601,735 Reduced 63.09%	3,276,996 $48.9 Million
Q3 2023 Nov 13, 2023	SELL	$16.15 - $42.35 $40.6 Million - $106 Million	-2,511,814 Reduced 22.05%	8,878,731 $143 Million
Q2 2023 Aug 11, 2023	SELL	$40.29 - $82.51 $106 Million - $217 Million	-2,634,512 Reduced 18.78%	11,390,545 $473 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $66.3 Million - $140 Million	1,175,538 Added 9.15%	14,025,057 $843 Million
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $3.92 Million - $5.23 Million	61,280 Added 0.48%	12,849,519 $943 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $72.5 Million - $95.5 Million	1,065,755 Added 9.09%	12,788,239 $972 Million
Q2 2022 Aug 15, 2022	SELL	$56.6 - $89.9 $52.5 Million - $83.4 Million	-928,159 Reduced 7.34%	11,722,484 $815 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $1.6 Million - $2.25 Million	26,600 Added 0.21%	12,650,643 $1.05 Billion
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $266,008 - $432,210	3,543 Added 0.03%	12,624,043 $948 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $90 Million - $151 Million	774,799 Added 6.54%	12,620,500 $1.47 Billion
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $418 Million - $724 Million	3,208,178 Added 37.14%	11,845,701 $2.63 Billion
Q1 2021 May 14, 2021	BUY	$124.11 - $190.17 $111 Million - $170 Million	892,485 Added 11.52%	8,637,523 $1.14 Billion
Q4 2020 Feb 12, 2021	BUY	$112.16 - $174.14 $125 Million - $194 Million	1,115,021 Added 16.82%	7,745,038 $1.34 Billion
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $77 Million - $148 Million	1,326,769 Added 25.02%	6,630,017 $738 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $21 Million - $27.4 Million	367,900 Added 7.45%	5,303,248 $314 Million
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $5.7 Million - $9.57 Million	-99,972 Reduced 1.99%	4,935,348 $332 Million
Q4 2019 Feb 18, 2020	BUY	$68.3 - $93.8 $33,535 - $46,055	491 Added 0.01%	5,035,320 $424 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $12.4 Million - $19.6 Million	-199,983 Reduced 3.82%	5,034,829 $377 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $8.46 Million - $12.7 Million	200,415 Added 3.98%	5,234,812 $331 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $71.6 Million - $126 Million	2,240,586 Added 80.2%	5,034,397 $243 Million
Q4 2018 Feb 14, 2019	BUY	$28.72 - $52.63 $15.2 Million - $27.8 Million	528,500 Added 23.33%	2,793,811 $93.5 Million
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $12.4 Million - $20.3 Million	386,600 Added 20.58%	2,265,311 $119 Million
Q2 2018 Aug 14, 2018	BUY	$19.85 - $32.0 $37.3 Million - $60.1 Million	1,878,711 New	1,878,711 $58.8 Million

Others Institutions Holding NVCR

# of Institutions

265

Shares Held

79.4M

Call Options Held

970K

Put Options Held

118K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.88B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account

Capital World Investors Novo Cure LTD Transaction History